Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Emergent BioSolutionsFRA:ER4 +3.40%60 Equity-to-Asset is 0.31 as of Jun. 2026, which is 34% below its 10-year median of 0.47. GuruFocus rates FRA:ER4 with a GF Score™ of 60/100 and a GF Value™ of €4.37 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 1,007 Drug Manufacturers companies, Emergent BioSolutions ranks worse than 82.92% on this metric.
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Emergent BioSolutions Equity-to-Asset Related Terms
Emergent BioSolutions Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Emergent BioSolutions's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:ER4 vs ELTP, ANIK, AKBA: Equity-to-Asset Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Emergent BioSolutions's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Emergent BioSolutions Equity-to-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Emergent BioSolutions's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Emergent BioSolutions's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Emergent BioSolutions's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Emergent BioSolutions (FRA:ER4) has a Equity-to-Asset of 0.31 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Emergent BioSolutions and its competitors. This is 34% below median its historical median of 0.47. Over the past decade, Emergent BioSolutions' Equity-to-Asset has ranged from 0.26 to 0.85. According to the industry distribution chart, Emergent BioSolutions ranks #835 out of 1007 companies in the Drug Manufacturers industry, placing it in the top 82.9%.
Is Emergent BioSolutions' Equity-to-Asset too high?
Emergent BioSolutions' current Equity-to-Asset of 0.31 is 34% below median its 10-year median of 0.47. Over the past 10 years, this metric has ranged from a low of 0.26 to a high of 0.85. The Drug Manufacturers industry median Equity-to-Asset is 0.60. Emergent BioSolutions' value of 0.31 is 48.3% below this industry median. Based on the distribution chart, Emergent BioSolutions ranks #835 out of 1007 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Emergent BioSolutions has a GF Score™ of 60/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Emergent BioSolutions' Equity-to-Asset compare to ELTP and ANIK?
According to the Drug Manufacturers industry distribution chart, Emergent BioSolutions ranks #835 out of 1007 companies for Equity-to-Asset. This places Emergent BioSolutions in the lower half of its industry. The industry median Equity-to-Asset is 0.60. Emergent BioSolutions' value of 0.31 is 48.3% below this benchmark. Historically, Emergent BioSolutions' own Equity-to-Asset has ranged from 0.26 to 0.85 over the past decade. While the company's 10-year median is 0.47 vs. the industry median of 0.60, Emergent BioSolutions has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Drug Manufacturers company?
The median Equity-to-Asset among Drug Manufacturers companies is 0.60, based on 1,007 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Emergent BioSolutions's current Equity-to-Asset of 0.31 is 48.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Emergent BioSolutions and its competitors. For the Drug Manufacturers industry, the median Equity-to-Asset is 0.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Emergent BioSolutions's current Equity-to-Asset is 0.31, which is 34% below median its own 10-year median of 0.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Emergent BioSolutions stock overvalued right now?
Based on GuruFocus' analysis, Emergent BioSolutions (FRA:ER4) is currently considered Significantly Overvalued. The stock's GF Value™ is €4.37, compared to a current price of €6.08 — trading 39.1% above its estimated fair value. The current Equity-to-Asset is 0.31, which is 34% below median its 10-year median of 0.47 and 48.3% below the Drug Manufacturers industry median of 0.60. Emergent BioSolutions' overall GF Score™ is 60/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Emergent BioSolutions (FRA:ER4), the current Equity-to-Asset is 0.31 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Emergent BioSolutions (FRA:ER4) Overvalued in 2026?
Based on GuruFocus' analysis, Emergent BioSolutions stock appears to be overvalued.
The current stock price of €6.08 is trading 39.1% above its estimated GF Value™ of €4.37.
GuruFocus considers Emergent BioSolutions to be Significantly Overvalued.
Key valuation signals for FRA:ER4:
Equity-to-Asset: 0.31 (34% below median its 10-year median of 0.47)
GF Value™: €4.37 vs. price of €6.08 (39.1% above fair value)
Industry Position: 48.3% below the Drug Manufacturers median (#835 of 1007)
No single metric tells the full story. See the FRA:ER4 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. Geographically, the company operates in United States, Canada, and Others. It derives maximum revenue from United states. The company's products include: NARCAN Nasal Spray, KLOXXADO Nasal Spray, ACAM2000, ANTHRASIL, BAT, BioThrax, CNJ-016, raxibacumab injection, Ebanga, and others.
60GF Score
Get the complete analysis for FRA:ER4
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:ER4 has been successfully added to your 
